Results 161 to 170 of about 10,116 (213)

Neurophysiological effects of botulinum toxin type a

Neurotoxicity Research, 2006
Botulinum toxin type A (BoNT-A) acts peripherally by inhibiting acetylcholine release from the presynaptic neuromuscular terminals, thus weakening muscle contraction, and its clinical benefit depends primarily on the toxin's peripheral action. In addition to acting directly at the neuromuscular junction, the toxin alters sensory inputs to the central ...
ABBRUZZESE, GIOVANNI, BERARDELLI A.
openaire   +3 more sources

Botulinum toxin type A for facial wrinkles

Cochrane Database of Systematic Reviews, 2021
Botulinum toxin type A (BontA) is the most frequent treatment for facial wrinkles, but its effectiveness and safety have not previously been assessed in a Cochrane Review.To assess the effects of all commercially available botulinum toxin type A products for the treatment of any type of facial wrinkles.We searched the following databases up to May 2020:
Cristina Pires, Camargo, Jun, Xia, Caroline S, Costa, Rolf, Gemperli, Maria Dc, Tatini, Max K, Bulsara, Rachel, Riera   +6 more
openaire   +2 more sources

Clinical use of non-a botulinum toxins: botulinum toxin type B

Neurotoxicity Research, 2006
Botulinum neurotoxin type B (BT, BT-B) has been used as NeuroBloc/MyoBloc since 1999 for treatment of cervical dystonia, hyperhidrosis, spastic conditions, cerebral palsy, hemifacial spasm, bladder dysfunction, spasmodic dysphonia, sialorrhoea, anal fissures, piriformis syndrome, various pain conditions and cosmetic applications.
D, Dressler, R, Eleopra
openaire   +2 more sources

Botulinum toxin in tension-type headache

Journal of Neurology, 2004
Despite the controversy regarding specific mechanism of botulinum toxin action in pain relief, clinical results suggest that botulinum toxin type A may be promising treatment options for patients with primary chronic headache. To investigate this, we included sixteen patients with chronic tension-type headache in a prospective double blind, placebo ...
Telarović, Srđana, Relja, Maja
openaire   +6 more sources

Botulinum Toxin Type B for Dynamic Glabellar Rhytides Refractory to Botulinum Toxin Type A

Dermatologic Surgery, 2003
Botulinum toxin type B (BTX-B; Myobloc) has recently been introduced for the treatment of dynamic rhytides. This serotype is structurally similar to botulinum toxin type A (BTX-A; Botox) and appears to produce equivalent muscular paralysis. Because of the fact that some patients may become resistant to the effects of BTX-A with its continued use or may
Tina S, Alster, Jason R, Lupton
openaire   +2 more sources

Botulinum Toxin Type B

Dermatologic Surgery, 2003
Botulinum toxin B is an antigenically distinct form of Botulinum toxin which has unique physical and clinical properties that distinguish it from Botulinum toxin A.To describe properties of Botulinum toxin B.More rapid onset, greater diffusion characteristics as well as diminished longevity have been identified to date in previous studies.BTX-B is safe
openaire   +2 more sources

Botulinum toxin type B in antibody-induced botulinum toxin type A therapy failure

Journal of Neurology, 2003
Recently, it was reported that botulinum toxin type B complex (BoNT/B) (NeuroBloc(R), Elan Pharmaceuticals) can produce an adequate therapeutic response in patients with antibody induced failure of botulinum toxin type A complex (BoNT/A) therapy. We wanted to study whether this effect is transient or sustained.
Dirk, Dressler, Hans, Bigalke, Reiner, Benecke   +2 more
openaire   +2 more sources

Molecular Weight of Type A Botulinum Toxin

Infection and Immunity, 1970
Clostridium botulinum type A does not produce a 12,000 molecular weight toxin. The reported isolation of such a material by Gerwing et al. could not be confirmed.
J N, Knox, W P, Brown, L, Spero
openaire   +2 more sources

Botulinum Toxin Type B (Myobloc)

Dermatologic Surgery, 2003
Myobloc, known as Neurobloc in Europe, is a member of the botulinum toxin family. It has been used for a myriad of problems since its approval in the United States in December 2000. It is currently not approved for cosmetic use but has been used for this purpose. This article reviews what is currently known about botulinum toxin type B and its efficacy
Leslie, Baumann, Laura, Black
openaire   +2 more sources

Botulinum Toxin Type A in Dental Medicine

Journal of Dental Research, 2019
Botulinum toxins (BoNTs) are a product of the bacteria Clostridium botulinum. By entering nerve endings, they cleave and inactivate SNARE proteins, which are essential for neurotransmitter release. Prevention of acetylcholine release at the neuromuscular junction causes long-lasting and potentially fatal flaccid paralysis—a major feature of botulism ...
V.R.M. Muñoz Lora, A.A. Del Bel Cury, B. Jabbari, Z. Lacković   +3 more
openaire   +2 more sources